Journal of the American Medical Directors Association
JAMDA OnlineOriginal StudyHypertension and Its Treatment at Age 90 Years: Is There an Association with 5-Year Mortality?
Section snippets
Study Population
The study population is part of the Jerusalem Longitudinal Study (1990–2015), a prospective observational longitudinal study previously described.16, 17 The sample frame is the birth cohort born June 1, 1920, through May 31, 1921, resident in Western Jerusalem, all of whom were eligible for inclusion. There were no exclusion criteria. Subjects were randomly chosen from the national electoral register, and the sample has been proven to be representative, as shown by similar morbidity, mortality,
Results
A total of 480 subjects aged 90 years were assessed, among whom the prevalence of NORMO, NonTx-HTN, and Tx-HTN was 12.3% (59/480), 12.7% (61/480), and 75% (360/480), respectively, with mean BP of 124 ± 12/65 ± 7, 169 ± 54/76 ± 10, and 148 ± 29/70 ± 11 mmHg, respectively. Subjects with Tx-HTN were more likely to be depressed, less educated, sedentary, to have heart failure, ischemic heart disease, chronic kidney disease, lower total cholesterol, low-density lipoprotein (LDL), and hemoglobin. The
Discussion
This study describes the association between BP at age 90 years among a representative community dwelling sample and subsequent 5-year survival, after accounting for antihypertensive treatment, common comorbidities, functional status, and hand grip strength. The primary finding is a negative one. Compared to normotensives, untreated raised BP levels were not significantly associated with an increased mortality risk or reduced survival among nonagenarians. Indeed a recurring trend to emerge from
Conclusions and Implications
This observational study among a representative community-dwelling cohort failed to find a significant association between hypertensive status at age 90 years and 5-year mortality. Indeed, a tendency toward improved survival and reduced risk of mortality was observed in nontreated hypertensives, after adjusting for associated comorbidity, functional status, and muscle strength. Treating hypertension beyond the age of 90 years should remain a highly individualized decision, and despite the
References (36)
- et al.
Mortality and cardiovascular events are best predicted by low central/peripheral pulse pressure amplification and not by high blood pressure levels in elderly nursing home subjects: The PARTAGE study (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population) study
J Am Coll Cardiol
(2012) - et al.
Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician
J Psychiatr Res
(1975) - et al.
Bursztyn. Hypertension and 5 year mortality among 85 year olds: The Jerusalem Longitudinal Study
J Am Med Dir Assoc
(2012) Leiden research program on aging
Exp Gerontol
(2002)- et al.
American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: A report from the American Heart Association
Circulation
(2015) - et al.
An expert opinion from the European Society of Hypertension–European Union Geriatric Medicine Society Working Group on the management of hypertension in very old, frail subjects
Hypertension
(2016) - et al.
Rethinking the association of high blood pressure with mortality in elderly adults: The impact of frailty
Arch Intern Med
(2012) - et al.
Blood pressure and ten-year mortality risk in the Milan Geriatrics 75+ Cohort Study: Role of functional and cognitive status
Age Ageing
(2015) - et al.
Blood pressure and pulse wave velocity in the institutionalized elderly aged 80 and over: Baseline of the PARTAGE study
J Hypertens
(2010) - et al.
Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: The PARTAGE Study
JAMA Intern Med
(2015)
Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs
JAMA Intern Med
Treatment of hypertension in patients 80 years of age or older
N Eng J Med
SPRINT Research Group. A randomized trial of intensive versus standardized blood-pressure control
N Eng J Med
Intensive vs standardized blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. A randomized clinical trial
JAMA
2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Eur Heart J
2014 Evidence-based guidelines for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)
JAMA
No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: An investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind placebo-controlled study of antihypertensives in people with hypertension aged 80 and over
BMC Med
Characterizing frailty status in the systolic blood pressure intervention trial
J Gerontol A Biol Sci Med Sci
Cited by (0)
J. Stessman and M. Bursztyn contributed equally to the study.
This work was supported by funds from the Ministry of Senior Citizens of the State of Israel, and Eshel—the Association for the Planning and Development of Services for the Aged in Israel. No support was offered by any commercial venture. These funds were used exclusively to support the research effort, primarily as salaries to ancillary staff. No research funds were received by any author of this paper. The sponsors had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review, or approval of the manuscript.
The authors declare no conflicts of interest.